



**META HEALTH LIMITED**

(Incorporated in the Republic of Singapore)

(Company Registration No.: 198804700N)

---

**RESPONSES TO QUERIES RAISED BY SINGAPORE EXCHANGE REGULATION ON 11 FEBRUARY 2022**

---

The board of directors (the “**Board**”) of Meta Health Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) sets out its responses to the following queries raised by the Singapore Exchange Regulation (“**SGX**”) on 11 February 2022 in respect of the Company’s announcement dated 9 February 2022 relating to a strategic partnership between the Company’s wholly-owned healthcare platform company, 5Digital Pte. Ltd. (“**5Digital**”) and medical technology company, Aimedis B.V. (“**Aimedis**”) (the “**Announcement**”).

*Unless otherwise defined, all capitalised terms used in this announcement shall have the same meaning as ascribed to them in the Announcement.*

**SGX Query 1**

*Please provide details on the Company’s role in the partnership.*

**Company’s Response**

The role of 5Digital in the partnership agreement with Aimedis (“**Partnership**” or “**Agreement**”) is as follows:

- (i) hosting and licensing of Aimedis’ block chain based electronic medical record components within Singapore, Hong Kong and Indonesia, for an agreed licensing fee per patient record created;
- (ii) content creation (such as virtual buildings, virtual land, virtual services) on the Aimedis platform where such content shall be shared with and used by 5Digital within the community built by 5Digital;
- (iii) 5Digital will be offered an option to participate up to 25% of the fund raise by Aimedis in its series A round funding;
- (iv) second opinion medical consultations from other global regions to be offered to 5Digital’s community and all platform fees charged to end-consumers to be shared between Aimedis and 5Digital; and
- (v) Aimedis quality management makes sure established infrastructure is according to Aimedis’ requirements for quality, security and the general terms and infrastructure planning with 5Digital assistance in localisation and support.



**META HEALTH LIMITED**

(Incorporated in the Republic of Singapore)

(Company Registration No.: 198804700N)

**SGX Query 2**

*Will the partnership involve an issue of NFTs?*

**Company's Response**

The Company and 5Digital will not be issuing any NFTs in the Partnership and will continue to observe what Aimedis does in the United States and the European market on issue of NFTs.

**SGX Query 3**

*What is the expected capital outlay to the Company and what would be the Company's equity share?*

**Company's Response**

As at the date of this announcement, the Company and/or 5Digital do not expect any capital outlay in respect of the Partnership.

The Partnership does not stipulate a minimum investment sum or an equity issue by 5Digital and/or Aimedis. The Partnership provides for an option for 5Digital to participate in the next equity linked funding round by Aimedis. The Group understands that currently, Aimedis has been approaching venture capitalists in the United States and has yet to share any details on valuation or specific timeline for this matter.

The Company and/or 5Digital will use its existing platform integration team to work on the data sharing onto the Aimedis platform and the compliance of relevant local regulations such as PDPA on such integration.

**SGX Query 4**

*Does the Company's Board and management have expertise in this area? If not, who is advising / driving the discussions on this strategic partnership and going forward?*

**Company's Response**

Please refer to the Company's response to SGX Query 1 on the role of the 5Digital in the Partnership.

The current management team of 5Digital, namely Mr Ahillan Pupalasingam (Chief Investment Officer), Dr Vas Metupalle (Chief Medical Officer), Mr Mika Mikkonen (Business Development Manager), and the recently appointed Executive Director, Dr Bernard Ng, have relevant experience working on assessment of digital health platforms and deployments, with the various investments made in this area in 2021 by the Company. Dr Bernard Ng was formerly from a global pharmaceutical company as its medical director. For further information on Dr Bernard Ng, please refer to the Company's announcement dated 6 January 2022 on the appointment of Dr Bernard Ng as the Executive Director of 5Digital (being an Executive Officer of the Company).



## **META HEALTH LIMITED**

(Incorporated in the Republic of Singapore)

(Company Registration No.: 198804700N)

The core platform of Aimesis is a medical record system on the block chain and the creation of the virtual space is an extension to allow a safe environment for practice of medicine and wellness activities online. The founders of Aimesis are clinical doctors and the current management of 5Digital is working directly with these founder doctors to develop the framework in a secure environment. No plans have been made on opening this to any external platforms as yet.

### **SGX Query 5**

- (a) *What kind of due diligence will be done by the Company?*
- (b) *Which geographical area will the partnership be focused on?*

### **Company's Response**

- (a) Prior to the execution of the Partnership, 5Digital had, over the past months, created a market landscape and roadmap for platform planning and identified potential companies for partnership. 5Digital, having identified Aimesis as a credible potential partner, conducted in-person meetings in Dubai with the founders of Aimesis, and reviewed the platform and discussed the roadmap for the various new developments planned and business model.

Going forward, further legal and regulatory opinion will be sought on components of the rollout of and the platform and features will be rolled out in stages after the diligence is satisfactory. This will include the storage of medical records within Singapore for the local instance and the PDPA and other security requirements. The licencing agreements with providers of health and wellness services for the spaces and community created will be similarly reviewed.

- (b) Based on 5Digital's preliminary discussions with some specialist medical clinicians and owners of wellness businesses, it is expected that Singapore shall be the first location for the virtual medical centre and associated spaces to be built [in respect of the Aimesis platform]. 5Digital has also commenced discussions with an electronic medical record company in Hong Kong and a licence of the Aimesis platform has been obtained from Aimesis on an exclusive basis for Hong Kong. Earlier on 14 October 2021, 5Digital announced an investment in an Indonesia joint venture company, PT Gaido Digital Medika, and this company is expected to replicate the technology for the local market in Jakarta and Bali, in Indonesia, in the near future.

### **SGX Query 6**

- (a) *Should such virtual medical cities be set up, what kind of revenue streams and expenses will be expected for the Company?*
- (b) *Will this business be classified under Healthcare Business or E-Commerce Business (under the diversification mandate)?*

### **Company's Response**

- (a) With the setting up of virtual medical cities, the Group can expect to generate revenue from both clinical services online and sale of over-the-counter health and wellness products.



**META HEALTH LIMITED**

(Incorporated in the Republic of Singapore)  
(Company Registration No.: 198804700N)

The virtual platform is seen as a way the Group can expand its current telemedicine business with a 3-dimensional environment and make technology advancements in this area with sharing of content for therapies that have been validated in the United States and Europe.

- (b) Such business shall be classified by the Company under the Healthcare Business under the diversification mandate approved by the Company's shareholders on 8 June 2021. There is opportunity for running an ePharmacy on a more robust visual platform than the current web portal is also in the roadmap, and this would be part of the approved E-Commerce Business segment.

**By Order of the Board**

Lee Wei Hsiung  
Company Secretary  
14 February 2022

---

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, ZICO Capital Pte. Ltd. (the "**Sponsor**"), in accordance with Rule 226(2)(b) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Alice Ng, Director of Continuing Sponsorship, ZICO Capital Pte. Ltd., at 8 Robinson Road #09-00 ASO Building, Singapore 048544, telephone (65) 6636 4201.